Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer

References

• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov . 2015;14:561–584. Available at http://www.nature.com/articles/nrd4591
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33:581–598.
   PubMed Web of Science ®Google Scholar
• Grenier JM, Yeung ST, Khanna KM. Combination immunotherapy: taking cancer vaccines to the next level. Front Immunol. 2018;8:1–9.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med [Internet]. 2010. [ cited 2018 Sep 22];363:711–723. Available at http://www.ncbi.nlm.nih.gov/pubmed/20525992
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med [Internet]. 2012. [ cited 2018 Oct 21];366:2455–2465. Available at http://www.nejm.org/doi/abs/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med [Internet]. 2015. [ cited 2018 Oct 21];372:2018–2028. Available at http://www.nejm.org/doi/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol [Internet]. 2018. [ cited 2018 May 16]; Available at http://www.nature.com/articles/s41577-018-0014-6
   Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer [Internet]. 2016. [ cited 2018 Dec 6];16:275–287. Available at http://www.ncbi.nlm.nih.gov/pubmed/27079802
   PubMed Web of Science ®Google Scholar
• Wargo JA, Reuben A, Cooper ZA, et al. Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol. [ cited 2018 Jul 1]; Available at https://www-ncbi-nlm-nih-gov.ezproxy.icr.ac.uk/pmc/articles/PMC4955940/pdf/nihms801775.pdf
   Web of Science ®Google Scholar
• Cooper ZA, Juneja VR, Sage PT, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res [Internet]. 2014. [ cited 2018 Oct 21];2:643–654. Available at http://www.ncbi.nlm.nih.gov/pubmed/24903021
   PubMed Web of Science ®Google Scholar
• Topalian S, Drake C, Pardoll DM, et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Elsevier Cancer Cell [Internet]. [ cited 2018 Dec 6]; Available at https://www.sciencedirect.com/science/article/pii/S1535610815000896
   Web of Science ®Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med [Internet]. 2018. [ cited 2019 Jul 19];10:eaar3342. Available at http://www.ncbi.nlm.nih.gov/pubmed/30021886
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res [Internet]. 2013. [ cited 2018 Jul 1];1:32–42. Available at http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-13-0013
   PubMed Web of Science ®Google Scholar
• Niyongere S, Saltos A, Gray JE. Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. J Thorac Dis. 2018;10:S433–S450.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res [Internet]. 2014. [ cited 2018 Jul 1];2:846–856. Available at http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-14-0040
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun [Internet]. 2016. [ cited 2018 Nov 24];7:12624. Available at http://www.nature.com/articles/ncomms12624
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen JB, et al. JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). OncologyPRO [Internet]. [ cited 2018 Dec 8]. Available at https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/JAVELIN-Renal-101-a-randomized-phase-3-study-of-avelumab-axitinib-vs-sunitinib-as-first-line-treatment-of-advanced-renal-cell-carcinoma-aRCC
   Web of Science ®Google Scholar
• Taieb J, Moehler M, Boku N, et al. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev [Internet]. 2018. [ cited 2018 May 12];66:104–113. Available at http://linkinghub.elsevier.com/retrieve/pii/S0305737218300380
   PubMed Web of Science ®Google Scholar
• Jing W, Li M, Zhang Y, et al. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther [Internet]. 2016. [ cited 2018 Jul 1];9:489. Available at http://www.ncbi.nlm.nih.gov/pubmed/26889087
   PubMed Web of Science ®Google Scholar
• Hodi F, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3. Lancet Oncol. 19;1480–1492. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.72.2850
   Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med [Internet]. 2018. [ cited 2018 Nov 24];378:1277–1290. Available at http://www.nejm.org/doi/10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol [Internet]. 2009. [ cited 2018 Dec 8];182:1885–1891. Available at http://www.ncbi.nlm.nih.gov/pubmed/19201841
   PubMed Web of Science ®Google Scholar
• Workman CJ, Vignali DAA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol [Internet]. 2005. [ cited 2018 Dec 8];174:688–695. Available at http://www.ncbi.nlm.nih.gov/pubmed/15634887
   PubMed Web of Science ®Google Scholar
• Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res [Internet]. 2012. [ cited 2018 Sep 25];72:917–927. Available at http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs Springer [Internet]. [ cited 2018 Dec 6]; Available at https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/article/10.1007/s10637-012-9866-y&casa_token=FpVL2LMec9oAAAAA:8C7C4UDvjAZGUcR5UZ8wdbXUTM-_PuHhW2F-cm_rZr7QhvgQFTcjOGREPebMFldnKoX8Hgiki8vQZe4A
   Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res [Internet]. 2009. [ cited 2018 Dec 6];15:6225–6231. Available at http://clincancerres.aacrjournals.org/content/early/2009/09/13/1078-0432.CCR-09-0068.abstract
   PubMed Web of Science ®Google Scholar
• Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med [Internet]. 2010. [ cited 2018 Dec 6];8:71. Available at http://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-8-71
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol [Internet]. 2017. [ cited 2018 Dec 6];35:9520–9520. Available at http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.9520
   Web of Science ®Google Scholar
• Rajalingam R. Overview of the killer cell immunoglobulin-like receptor system. Immunogenetics Springer [Internet]. 2012. [ cited 2018 Dec 6]; Available at https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/protocol/10.1007/978-1-61779-842-9_23&casa_token=igUlRqNIcKIAAAAA:bgeuh7LjoCSum5OL4-r89-9X1wD0QBuAd0eIXNLKZWY5Kn_wJm51gjXJqBN5AVAL8yIFpiid6087lkcL
   Google Scholar
• Vey N, Goncalves A, Karlin L, et al. A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). J Clin Oncol [ [Internet]]. 2015. [ cited 2018 Dec 6];33. Available at http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3065
   Web of Science ®Google Scholar
• Leidner R, Kang H, Haddad R, et al. Preliminary efficacy from a phase 1/2 study of the natural killer cell–targeted antibody, lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck. J Immunother Cancer [Internet]. [ cited 2018 Dec 6]; Available at https://innate-pharma.com/sites/default/files/leidner_sitc_2016_liri_001_efficacy_oral.pdf
   Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol [Internet]. [ cited 2018 Nov 24]; Available at https://www.nature.com/articles/nri1371
   Web of Science ®Google Scholar
• Redmond W The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol [Internet]. [ cited 2018 Nov 24]; Available at http://www.dl.begellhouse.com/journals/2ff21abf44b19838,18841dcb1a005a88,2abe17b4476658f5.html
   Web of Science ®Google Scholar
• Moran A, Polesso F, Weinberg A OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression. J Immunother Cancer [Internet]. 2014. [ cited 2018 Nov 24];2:O18. Available at http://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-S3-O18
   PubMedGoogle Scholar
• Redmond W Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. Am Assoc Immnol [Internet]. [ cited 2018 Nov 24]; Available at http://www.jimmunol.org/content/179/11/7244.short
   Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res [Internet]. 2013. [ cited 2018 Sep 25];73:7189–7198. Available at http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-12-4174
   PubMed Web of Science ®Google Scholar
• Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res [Internet]. 2017. [ cited 2018 Nov 24];23:6165–6177. Available at http://www.ncbi.nlm.nih.gov/pubmed/28855348
   PubMed Web of Science ®Google Scholar
• Redmond W, Linch S, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. AACR [Internet]. [ cited 2018 Nov 24]; Available at http://cancerimmunolres.aacrjournals.org/content/2/2/142.short?casa_token=m71Al4Xna_AAAAAA:g-eOUxMDnvwOj2R5s8nEJgexLtpRHyeUcZv48XwgcByFeO7QE_-MICFtqQcBOjX172eBUzFymQq-W7I
   Google Scholar
• Infante JR, Hansen AR, Pishvaian MJ, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J Clin Oncol [Internet]. 2016. [ cited 2018 Nov 24];34: 101–101. Available at http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.101
   Web of Science ®Google Scholar
• Knee D, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer Elsevier [Internet]. [ cited 2018 Nov 24]; Available at https://www.sciencedirect.com/science/article/pii/S0959804916323413
   Web of Science ®Google Scholar
• Koon HB, Shepard DR, Merghoub T, et al. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. J Clin Oncol [Internet]. 2016. [ cited 2018 Sep 25];34:3017–3017. Available at http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.3017
   Web of Science ®Google Scholar
• Tran B, Carvajal RD, Marabelle A, et al. Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors. J Clin Oncol [Internet]. 2017. [ cited 2018 Nov 24];35:2521–2521. Available at http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.2521
   Web of Science ®Google Scholar
• Siu LL, Steeghs N, Meniawy T, et al. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. J Clin Oncol [Internet]. 2017. [ cited 2018 Nov 24];35: 104–104. Available at http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.104
   Web of Science ®Google Scholar
• Oussa N, Soumounou Y, Sabbagh L TRAF1 phosphorylation on Serine 139 modulates NF-κB activity downstream of 4-1BB in T cells. Biochem Biophys Res Commun Elsevier [Internet]. [ cited 2018 Nov 24]; Available at https://www.sciencedirect.com/science/article/pii/S0006291X13001526
   Web of Science ®Google Scholar
• Nam K, Kang H, Shin S, et al. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. Am Assoc Immnol [Internet]. [ cited 2018 Nov 24]; Available at http://www.jimmunol.org/content/174/4/1898.short
   Google Scholar
• Segal N, Logan T, Hodi F, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. AACR [Internet]. [ cited 2018 Nov 24]; Available at http://clincancerres.aacrjournals.org/content/23/8/1929.abstract
   Google Scholar
• Hematology/Oncology® ES-AJ of, 2017 undefined. TNFR agonists: a review of current biologics targeting OX40, 4-1BB, CD27, and GITR. gotoper.com [Internet]. [ cited 2018 Nov 24]. Available from: http://www.gotoper.com/publications/ajho/2017/2017november/tnfr-agonists-a-review-of-current-biologics-targeting-ox40-4-1bb-cd27-and-gitr
   Google Scholar
• Massarelli E, Segal NRV. Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies. J Immunother Cancer. 42016;Suppl 1:O7.
   Google Scholar
• van de Ven K, Borst J Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy [Internet]. 2015. [ cited 2018 Nov 24];7:655–667. Available at https://www.futuremedicine.com/doi/10.2217/imt.15.32
   PubMed Web of Science ®Google Scholar
• Burris H, Infante J Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol [Internet]. [ cited 2018 Nov 24]; Available at http://mary-crowley-web.s3.amazonaws.com/media/filer_public/3b/6f/3b6f030e-4e0a-4bac-a52c-0a7db2f499ab/354_-_safety_and_activity_of_varlilumab_a_novel_and_first-in-class_agonist_anti-cd27_antibody_in_patients_with_advanced_solid_tumors.pdf
   Web of Science ®Google Scholar
• Sanborn RE, Pishvaian MJ, Kluger H, et al. Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody, nivolumab, in advanced cancer patients. J Clin Oncol [Internet]. [ cited 2018 Nov 24]; Available at https://celldex.com/docs/VARLI_2017ASCO_Sanborn.pdf
   Web of Science ®Google Scholar
• Owonikoko T, Hussain A, Stadler WM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol Springer [Internet]. [ cited 2018 Nov 24]; Available at https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/article/10.1007/s00280-015-2909-2&casa_token=SQ6Hj3YTZWoAAAAA:cmP_j-Kg-2EAkGMOWoW39RqTuTe3Mq78p9-z-2X35rO4y9Qtj-a2gRwelgRSj60LVa2kZ9hfmpqP5c6E
   Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol [Internet]. 2018. [ cited 2018 Nov 24];11:39. Available at https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0582-8
   PubMed Web of Science ®Google Scholar
• Yap TA, Burris HA, Kummar S, et al. ICONIC: biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 ± nivolumab (nivo) in patients (pts) with advanced cancers. J Clin Oncol [Internet]. 2018. [ cited 2018 Dec 8];36:3000–3000. Available at http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3000
   Web of Science ®Google Scholar
• Gupta S, Grilley-Olson J, Hong D, et al. Abstract CT091: safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. Cancer Res [Internet]. 2017. [ cited 2018 Nov 24];77:CT091–CT091. Available at http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2017-CT091
   Web of Science ®Google Scholar
• Readett DRJ, Denis L, Krieg AM, et al. PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-smal cell lung cancer (NSCLC). 12th World Congr. Lung Cancer. 2007;2(8):S461. Seoul, Korea.
   Google Scholar
• Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. science [Internet]. [ cited 2018 Nov 24]; Available at http://science.sciencemag.org/content/339/6121/786.short?casa_token=9mzjjm8AE9UAAAAA:Vb9bCjql3rEpjgvfXMFiI1F6VcK7ycjJV8xpszH7TlBvNPcJMK92B-cwuwQ4ZxRcMTZxufpLO3lEFw
   Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep [Internet]. 2015. [ cited 2018 Nov 24];11:1018–1030. Available at https://www.sciencedirect.com/science/article/pii/S2211124715004325
   PubMed Web of Science ®Google Scholar
• Corrales L The host STING pathway at the interface of cancer and immunity. Am Soc Clin Investig [Internet]. [ cited 2018 Nov 24]; Available at https://www.jci.org/articles/view/86892
   Google Scholar
• John L, Devaud C, Duong C, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. AACR [Internet]. [ cited 2018 Dec 6]; Available at http://clincancerres.aacrjournals.org/content/early/2013/07/19/1078-0432.CCR-13-0458.short
   Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res [Internet]. 2011. [ cited 2018 Sep 25];17:4550–4557. Available at http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-11-0116
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang W-T, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med [Internet]. 2015. [ cited 2018 Dec 6];373:1040–1047. Available at http://www.ncbi.nlm.nih.gov/pubmed/26352815
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol [Internet]. 2015. [ cited 2018 Dec 6];33:540–549. Available at http://ascopubs.org/doi/10.1200/JCO.2014.56.2025
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res [Internet]. 2015. [ cited 2018 Dec 6];21:1019–1027. Available at http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-2708
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med [Internet]. 2015. [ cited 2018 Dec 6];21:914–921. Available at http://www.nature.com/articles/nm.3910
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest [Internet]. 2016. [ cited 2018 Dec 6];126:3130–3144. Available at https://www.jci.org/articles/view/83092
   PubMed Web of Science ®Google Scholar
• Moon EK, Wang L-C, D V D, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res [Internet]. 2014. [ cited 2018 Dec 6];20:4262–4273. Available at http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-13-2627
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Lee SM, Thompson JA, et al. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med [Internet]. 2016. [ cited 2018 Dec 6];213:1133–1139. Available at http://www.jem.org/lookup/doi/10.1084/jem.20152021
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov [Internet]. 2015. [ cited 2018 Dec 6];14:642–662. Available at http://www.ncbi.nlm.nih.gov/pubmed/26323545
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol [Internet]. 2015. [ cited 2018 Dec 6];33:2780–2788. Available at http://ascopubs.org/doi/10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell [Internet]. 2017. [ cited 2018 Dec 6];170:1109–1119.e10. Available at http://www.ncbi.nlm.nih.gov/pubmed/28886381
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol [Internet]. 2018. [ cited 2018 Sep 25];36:1658–1667. Available at http://ascopubs.org/doi/10.1200/JCO.2017.73.7379
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Ribas A, et al. Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J Clin Oncol [Internet]. 2016. [ cited 2018 Sep 25];34:9568–9568. Available at http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.9568
   Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol [Internet]. [ cited 2018 Dec 6]; Available at https://www.nature.com/nrclinonc/journal/v11/n9/abs/nrclinonc.2014.111.html
   Web of Science ®Google Scholar
• Bakdash G, Buschow S, Gorris M, et al. Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. AACR [Internet]. [ cited 2018 Dec 6]; Available at http://cancerres.aacrjournals.org/content/early/2016/06/18/0008-5472.CAN-15-1695.short
   Google Scholar
• Van EA, Hurwitz A, Allison JP Combination immunotherapy of B16 melanoma using anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and granulocyte/macrophage colony. J Exp Med [Internet]. [ cited 2018 Dec 6]; Available at http://jem.rupress.org/content/190/3/355.abstract
   Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res [Internet]. 2015. [ cited 2018 Dec 6];21:712–720. Available at http://www.ncbi.nlm.nih.gov/pubmed/25524312
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature [Internet]. 2017. [ cited 2018 Dec 6];547:222–226. Available at http://www.nature.com/doifinder/10.1038/nature23003
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature [Internet]. 2017. [ cited 2018 Dec 6];547:217–221. Available at http://www.ncbi.nlm.nih.gov/pubmed/28678778
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature [Internet]. 2002. [ cited 2018 Sep 20];417:949–954. Available at http://www.ncbi.nlm.nih.gov/pubmed/12068308
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell [Internet]. 2004. [ cited 2018 Nov 24];116:855–867. Available at https://www.sciencedirect.com/science/article/pii/S0092867404002156
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res [Internet]. 2013. [ cited 2018 Dec 6];19:598–609. Available at http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-12-2731
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res [Internet]. 2013. [ cited 2018 Dec 6];19:1225–1231. Available at http://www.ncbi.nlm.nih.gov/pubmed/23307859
   PubMed Web of Science ®Google Scholar
• Mandalà M, De Logu F, Merelli B, et al. Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab Investig [Internet]. 2017. [ cited 2018 Dec 8];97:166–175. Available at http://www.nature.com/articles/labinvest2016132
   PubMed Web of Science ®Google Scholar
• Puzanov I, Callahan M, Linette G, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive. 2014. [ cited 2018 Dec 8]. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2511
   Google Scholar
• Ribas A, Lutzky BM, Lawrence D, et al. Phase 1 study combining anti-PD-L1 (MEDI4736) with BRAF (Dabrafenib) and/or MEK (Trametinib) inhibitors in advanced melanoma. [Internet]. [ cited 2018 Dec 6]. Available from: https://www.primeoncology.org/app/uploads/prime_activities/7893/ASCO-US-VSP-Abstract-3003-Ribas.pdf
   Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med [Internet]. 2007. [ cited 2018 Nov 24];356:2271–2281. Available at http://www.nejm.org/doi/abs/10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Hsieh J, Purdue M, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers [Internet]. [ cited 2018 Dec 4]; Available at https://www.nature.com/articles/nrdp20179
   Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol [Internet]. 2013. [ cited 2018 Nov 24];31:3791–3799. Available at http://www.ncbi.nlm.nih.gov/pubmed/24019545
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet [Internet]. 2007. [ cited 2018 Nov 24];370:2103–2111. Available at https://www.sciencedirect.com/science/article/pii/S0140673607619047
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med [Internet]. 2015. [ cited 2018 Nov 24];373:1803–1813. Available at http://www.nejm.org/doi/10.1056/NEJMoa1510665
   PubMed Web of Science ®Google Scholar
• Bex A, Etto T, Vyth-Dreese F, et al. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? Curr Oncol Rep [Internet]. 2012. [ cited 2018 Nov 24];14:230–239. Available at http://link.springer.com/10.1007/s11912-012-0229-9
   PubMed Web of Science ®Google Scholar
• Roland CL, Lynn KD, Toombs JE, et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. Zimmer J, editor. PLoS One [Internet]. 2009. [ cited 2018 Nov 24];4:e7669. Available at http://dx.plos.org/10.1371/journal.pone.0007669
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Toomey S, et al. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron [Internet]. 2015. [ cited 2018 Nov 24];8:15–21. Available at http://link.springer.com/10.1007/s12307-014-0160-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol [Internet]. 2018. [ cited 2018 Nov 24];36:578–578. Available at http://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.578
   Web of Science ®Google Scholar
• Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol [Internet]. 2018. [ cited 2018 Nov 24];19:405–415. Available at https://www.sciencedirect.com/science/article/pii/S1470204518300810
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med [Internet]. 2019. [ cited 2019 Mar 4];NEJMoa1816714. Available at http://www.nejm.org/doi/10.1056/NEJMoa1816714
   Web of Science ®Google Scholar
• Choueiri T, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol Elsevier [Internet]. [ cited 2018 Nov 24]; Available at https://www.sciencedirect.com/science/article/pii/S1470204518301074
   Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med [Internet]. 2019. [ cited 2019 Mar 4];NEJMoa1816047. Available at http://www.nejm.org/doi/10.1056/NEJMoa1816047
   Web of Science ®Google Scholar
• Chowdhury S, McDermott DF, Voss MH, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol [Internet]. 2017. [ cited 2018 Nov 24];35: 4506–4506. Available at http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.4506
   Web of Science ®Google Scholar
• Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the checkMate 016 study. [2019 Feb 3]. DOI:10.1186/s40425-018-0420-0
   Google Scholar
• Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity [Internet]. 2005. [ cited 2018 Nov 24];22:633–642. Available at http://linkinghub.elsevier.com/retrieve/pii/S1074761305001081
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. Am Assoc Immnol [Internet]. [ cited 2018 Nov 24]; Available at http://www.jimmunol.org/content/176/11/6752.short
   Google Scholar
• Godin-Ethier J, Hanafi L, Piccirillo CA, et al. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. AACR [Internet]. [ cited 2018 Nov 24]; Available at http://clincancerres.aacrjournals.org/content/17/22/6985.short
   Google Scholar
• Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med [Internet]. [ cited 2018 Nov 24]; Available at https://www.nature.com/articles/nm934
   Web of Science ®Google Scholar
• Holmgaard R, Zamarin D, Munn DH, et al. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med [Internet]. [ cited 2018 Nov 24]; Available at http://jem.rupress.org/content/early/2013/06/04/jem.20130066.short
   Web of Science ®Google Scholar
• Nayak A, Hao Z, Sadek R, et al. Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. [Internet]. [ cited 2018 Nov 24]. Available from: https://qfuse.com/client_downloads/ESMO2015_GDC-0919_Nayak_22Sep15.pdf
   Google Scholar
• Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol [Internet]. 2017. [ cited 2018 Nov 24];146:484–490. Available at https://www.sciencedirect.com/science/article/pii/S0090825817310223
   PubMed Web of Science ®Google Scholar
• Gangadhar TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO-202/KEYNOTE-037. Ann Oncol [ [Internet]]. 2016. [ cited 2018 Nov 24];27. Available at http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdw379.06/2799921/Epacadostat-plus-pembrolizumab-in-patients-with
   Google Scholar
• Perez RP, Riese MJ, Lewis KD, et al. Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I/II results of ECHO-204. J Clin Oncol [Internet]. 2017. [ cited 2018 Nov 24];35:3003–3003. Available at http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.3003
   Web of Science ®Google Scholar
• NewLink genetics announces initial phase 1 data with indoximod plus radiation and chemotherapy for pediatric patients with Diffuse Intrinsic Pontine Glioma (DIPG) presented during AACR plenary nasdaq: NLNK. [Internet]. [ cited 2018 Dec 4]. Available from: https://globenewswire.com/news-release/2018/04/15/1471681/0/en/NewLink-Genetics-Announces-Initial-Phase-1-Data-with-Indoximod-Plus-Radiation-and-Chemotherapy-for-Pediatric-Patients-with-Diffuse-Intrinsic-Pontine-Glioma-DIPG-Presented-During-AA.html
   Google Scholar
• An investigational immuno-therapy study of BMS-986205 combined with nivolumab, compared to nivolumab by itself, in patients with advanced melanoma - full text view - clinicaltrials.gov. [Internet]. [ cited 2018 Dec 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03329846
   Google Scholar
• Song M, Chen X, Wang L, et al. Future of anti-PD-1/PD-L1 applications: combinations with other therapeutic regimens. Chin J Cancer Res. 2018;4:157–172.
   Web of Science ®Google Scholar
• Mkrtichyan M, Najjar YG, Raulfs EC, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol [Internet]. 2011. [ cited 2018 Dec 6];41:2977–2986.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol [Internet]. 2017. [ cited 2018 Dec 6];18:312–322. Available at https://linkinghub.elsevier.com/retrieve/pii/S1470204517300657
   PubMed Web of Science ®Google Scholar
• Song M, Chen X, Wang L, et al. Future of anti-PD-1/PD-L1 applications: combinations with other therapeutic regimens. Chin J Cancer Res [Internet]. 2018. [ cited 2018 Dec 6];30:157–172. Available at http://www.cjcrcn.org/article/html_9792.html
   PubMed Web of Science ®Google Scholar
• Black M, Barsoum IB, Truesdell P, et al. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget [Internet]. 2016. [ cited 2018 Dec 6];7:10557–10567. Available at http://www.oncotarget.com/fulltext/7235
   PubMedGoogle Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med [Internet]. 2018;NEJMoa1801005. Available at http://www.nejm.org/doi/10.1056/NEJMoa1801005
   Web of Science ®Google Scholar
• Rodriguez-Pascual J, Cheng E, Maroto P, et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs [Internet]. 2010. [ cited 2018 Apr 22];21:478–486. Available at http://www.ncbi.nlm.nih.gov/pubmed/20401967
   PubMed Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol [Internet]. 2017. [ cited 2018 Sep 25];18:1009–1021. Available at https://linkinghub.elsevier.com/retrieve/pii/S1470204517305168
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature [Internet]. 2017. [ cited 2018 Dec 6];551:512–516. Available at http://www.nature.com/doifinder/10.1038/nature24462
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science [Internet]. 2015. [ cited 2018 Dec 6];348:124–128. Available at http://www.sciencemag.org/cgi/doi/10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Yuraszeck TM, Li -C-C, et al. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci [Internet]. 2016. [ cited 2019 Feb 3];9:89–104. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351311/pdf/CTS-9-089.pdf
   PubMed Web of Science ®Google Scholar